First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.
Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Yifan Zhai(Unknown), Hengbang Wang, Dajun Yang, Cunlin Wang, Lei Fu, Zhiyan Liang(East China University of Science and Technology), Yuefen Tang, Drew Rasco(Texas Oncology), Jason Chen(Brigham and Women's Hospital), Ming Lu, Qi Zeng(Sun Yat-sen University)
Cited by 20
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
|Clinical Cancer Research|2012|432
LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response
|The Journal of Immunology|2000|402